Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2014

TORONTO, ONTARIO--(Marketwired - Sept. 16, 2014) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) today announced its results for the fiscal year ended June 30, 2014. The Audited Financial Statements and Management's Discussion and Analysis for the year ended June 30, 2014 may be viewed on SEDAR at www.sedar.com.

Operational Highlights

• On January 8, 2014, Revive announced that it has begun trading on the TSX Venture Exchange under the symbol "RVV".
• On January 15, 2014, Revive announced the initiation of a Phase 2a proof of concept study of REV-001, for the prevention of opioid-induced respiratory depression.
• On February 12, 2014, Revive announced interim results of the first eight patients from its ongoing Phase 2a proof-of-concept study of REV-001, for the prevention of opioid-induced respiratory depression.
• On February 20, 2014, Revive announced that is has signed a material transfer agreement (the "MTA") with a global pharmaceutical company headquartered in Osaka, Japan. Pursuant to the MTA, Revive will have access to confidential information and clinical trial supply of the drug Bucillamine for Revive's human clinical trial of REV-002, a potential new treatment for gout. In return, the global pharmaceutical company will have exclusive commercialization rights in Japan, Korea and Taiwan, and Revive will have exclusive commercialization rights in the rest of the world.
• On April 30, 2014, Revive announced that it has submitted a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) for its Gout drug candidate, REV-002.
• On May 14, 2014, Revive announced positive pre-clinical results for Rett Syndrome, a rare disease.
• On June 5, 2014, Revive announced that it has submitted a pre-IND package to the U.S. FDA for its Gout drug candidate, REV-002.
• On June 27, 2014, Revive announced positive results from the second-half of its Phase 2a proof-of-concept study of REV-001, targeted for the treatment and/or prevention of opioid-induced respiratory depression.

Financial Highlights